3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
37
Carcinoma, Non-Small-Cell Lung
23
Uterine Cervical Neoplasms
22
Melanoma
22
Carcinoma, Renal Cell
18
Endometrial Neoplasms
16
Colorectal Neoplasms
15
Carcinoma, Transitional Cell
15
Triple Negative Breast Neoplasms
13
Stomach Neoplasms
13
Fallopian Tube Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Carcinoma, Hepatocellular
10
Pancreatic Neoplasms
9
Breast Neoplasms
9
Head and Neck Neoplasms
8
Carcinoma, Ovarian Epithelial
8
Carcinoma, Merkel Cell
8
Small Cell Lung Carcinoma
7
Prostatic Neoplasms
7
Neoplasms
7
Neoplasm Metastasis
7
Lung Neoplasms
6
Esophageal Neoplasms
6
Cholangiocarcinoma
6
Urinary Bladder Neoplasms
5
Mesothelioma
5
Lymphoma
4
Carcinosarcoma
4
Vulvar Neoplasms
3
Interventions
rucaparib
1
olaparib
1
Tretinoin
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Nivolumab
×
Gynecologic
×
Clear all
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts